Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2017 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG ; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G. | The Lancet | 2654 | 2396 |